Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

PLA2 inhibitors with broad potential application as antiinflammatory agents

Dec. 16, 1998

Cytogen obtains expanded rights to samarium Sm 153 lexidronam for RA

Dec. 11, 1998

Immune Response receives broader patent protection for RA vaccine technology

Dec. 10, 1998

New approval obtained for Nycomed's Xefo

Dec. 9, 1998

U.S. patent allowed for Vasogen's patient-specific therapy of autoimmune diseases

Dec. 8, 1998

Astra claims novel NOS inhibitors for asthma, rheumatoid arthritis and pain

Dec. 7, 1998

Optimum compound from COX-2 inhibitor series identified by Merck Frosst

Dec. 4, 1998

American Home Products describes preferential COX-2 inhibitors

Dec. 3, 1998

Advisory committee recommends approval of Celebrex for arthritis and further discussions for pain

Dec. 2, 1998

Dual 5-LO/COX inhibitor from Eisai displays potent antiinflammatory efficacy in vivo

Dec. 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...